Last updated: 9/02/2020.
Since hitting $140 in August 2019, Haemonetics' stock is down 37% from its high print. It's trailed the S&P 500 over one year but outperformed over three and five-year periods.
What's its chart telling us?
- The stock held the $70.00-$82.30 demand (support zone).
- It last tested this zone in February & April, 2019 (purple arrow). And rallied ~70% over the next six months.
- Beginning Value = Support level at $82.
- Ending Value = Previous all-time at $140.
*These are potential returns based on the price making it back to its all-time high. There's no guarantee it will happen.
What they do:
Haemonetics ($HAE) makes hematology products that help improve patient care and reduce the cost of healthcare.
Note: Hematology is the study of blood and blood disorders. Learn more about hematology and why it’s essential.
They have three business units: Plasma, Blood Center, and Hospital.
- Plasma-This unit provides plasma collection devices, disposables, and software for biopharmaceutical companies.
- Blood Center-This unit makes blood collection and software products.
- Hospital-This unit makes devices for measuring the coagulation of blood. And disposables and software that facilitate blood transfusions and cell processing.
For more details on their business, start reading on page 2 of its annual report.
- Biopharmaceutical companies
- Blood collection groups and independent blood centers
- Hospitals and national health organizations
They have a direct sales force and independent distributors. They target the decision-makers within each organization.
Note: In fiscal 2020, 2019, and 2018, their ten largest customers accounted for 54%, 52%, and 45% of their net revenues.
|# of Employees||3,300|
|Market Cap.||$4.53 billion|
|TTM Revenue||$945.6 million|
|KEY FINANCIALS||TTM, $ in millions|
|Net Income Margin||10.1%|
|Free Cash Flow||$101.3|
|Free Cash Flow Margin||10.7%|
|Return on Assets||7.0%|
|Return on Invested Capital (ROIC)||8.6%|
|Return on Equity||15.9%|